Literature DB >> 30343868

The Potential Role of Vedolizumab in Concomitant Eosinophilic Esophagitis and Crohn's Disease.

Tiffany H Taft1, Ece A Mutlu2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30343868     DOI： 10.1016/j.cgh.2018.06.022

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  5 in total

1.  Resolution of Refractory Eosinophilic Esophagitis with the Leukocyte-Trafficking Inhibitor Natalizumab.

Authors:  Ian L P Beales
Journal:  Dig Dis Sci       Date:  2019-06-12       Impact factor: 3.199

Review 2.  Emerging therapies for eosinophilic esophagitis.

Authors:  Thomas Greuter; Ikuo Hirano; Evan S Dellon
Journal:  J Allergy Clin Immunol       Date:  2019-11-06       Impact factor: 10.793

Review 3.  Eosinophilic Esophagitis: Existing and Upcoming Therapies in an Age of Emerging Molecular and Personalized Medicine.

Authors:  Ian F Slack; Justin T Schwartz; Vincent A Mukkada; Shawna Hottinger; J Pablo Abonia
Journal:  Curr Allergy Asthma Rep       Date:  2020-06-06       Impact factor: 4.806

Review 4.  Pathophysiology of Non-IgE-Mediated Food Allergy.

Authors:  Shouling Zhang; Scott Sicherer; M Cecilia Berin; Amanda Agyemang
Journal:  Immunotargets Ther       Date:  2021-12-29

Review 5.  Type 2 Inflammation in Eosinophilic Esophagitis: From Pathophysiology to Therapeutic Targets.

Authors:  Francesca Racca; Gaia Pellegatta; Giuseppe Cataldo; Edoardo Vespa; Elisa Carlani; Corrado Pelaia; Giovanni Paoletti; Maria Rita Messina; Emanuele Nappi; Giorgio Walter Canonica; Alessandro Repici; Enrico Heffler
Journal:  Front Physiol       Date:  2022-01-12       Impact factor: 4.566
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.